ArticleInternational journal of clinical and experimental pathology2018
MicroRNA-129-3p functions as a tumor suppressor in serous ovarian cancer by targeting BZW1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- PDK4 as a tumor suppressor in gastric cancer: implications for metabolic regulation, immune modulation, and prognostic potential.Discover oncology · 2025Article
- MicroRNA-129-3p Suppresses Tumor Progression and Chemoradioresistance in Head and Neck Squamous Cell Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Identification of miRNAs that target Fcγ receptor-mediated phagocytosis during macrophage activation syndrome.Frontiers in immunology · 2024Article
- Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation.Nature communications · 2022Article
- MicroRNA-129-1-3p Represses the Progression of Triple-Negative Breast Cancer by Targeting the GRIN2D Gene.BioMed research international · 2022Article
- Differentially Expressed Circular RNA Profile Signatures Identified in Prolificacy Trait of Yunshang Black Goat Ovary at Estrus Cycle.Frontiers in physiology · 2022Article
- CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3.Journal of ovarian research · 2021Article
- Role of microRNA-129 in cancer and non-cancerous diseases (Review).Experimental and therapeutic medicine · 2021Review
- Deciphering the role of microRNAs in mustard gas-induced toxicity.Annals of the New York Academy of Sciences · 2021Review
- Long non‑coding RNA NEAT1 modifies cell proliferation, colony formation, apoptosis, migration and invasion via the miR‑4500/BZW1 axis in ovarian cancer.Molecular medicine reports · 2020Article
- Biomarkers, Master Regulators and Genomic Fabric Remodeling in a Case of Papillary Thyroid Carcinoma.Genes · 2020Article
- Article
- Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aberrant expression of microRNAs (miRNAs) underlies a series of human diseases, including ovarian cancers. In our previous study, we found that miR-129-1-3p and miR-129-2-3p levels were significantly decreased in serous ovarian cancer via a microarray and quantitative PCR. In this study, we investigated the pathological role of miR-129-3p in an ovarian cancer cell line, SKOV3 cells. The results demonstrated that miR-129-3p overexpression distinctively inhibited the proliferation, migration, and invasion of ovarian cancer cells. The regulator of cell cycling, BZW1 (basic leucine zipper and W2 domains 1), was validated as a novel direct target of miR-129-3p. Specifically, miR-129-3p bound directly to the 3' untranslated region of BZW1 and suppressed its expression. Our results indicate that miR-129-3p serves as a tumor suppressor by targeting BZW1 in ovarian cancer cells and highlight that the restoration of miR-129-3p might be a novel therapeutic strategy for ovarian cancer.
Indexed as
Identifiers
31949677PMC6963061W3008684703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.